Artivion Reports Strong Q4 & Full Year 2025 Results, Returns to Profitability, and Issues Positive 2026 Guidance

summarizeSummary

Artivion, Inc. announced strong Q4 and full year 2025 financial results, returning to GAAP net income and reporting significant revenue and adjusted EBITDA growth, alongside positive 2026 guidance.

check_boxKey Events

• Strong Q4 2025 Financial Performance

  Reported GAAP revenue of $116.0 million and adjusted revenue of $118.3 million, an 18% increase on an adjusted constant currency basis year-over-year. GAAP net income was $2.4 million ($0.05 per diluted share), a significant improvement from a net loss in Q4 2024.

• Full Year 2025 Profitability Turnaround

  Achieved GAAP net income of $9.8 million for the full year 2025, reversing a net loss of $(13.4) million in 2024. Adjusted revenue for the full year was $443.6 million, up 13% on an adjusted constant currency basis.

• Significant Adjusted EBITDA Growth

  Adjusted EBITDA increased 29% to $22.7 million in Q4 2025 and 26% to $89.6 million for the full year 2025, demonstrating strong operational leverage.

• Positive 2026 Financial Outlook

  Issued 2026 revenue guidance in the range of $486 to $504 million, representing 10% to 14% growth, and adjusted EBITDA guidance of $105 to $110 million, indicating 18% to 22% growth.

auto_awesomeAnalysis

Artivion, Inc. delivered robust financial results for both the fourth quarter and full year 2025, marking a significant turnaround from net losses in the prior year to profitability. The company demonstrated strong revenue growth, particularly in stent grafts and On-X products, and substantial adjusted EBITDA expansion. The positive momentum is expected to continue into 2026, with management forecasting double-digit revenue growth and even faster adjusted EBITDA growth. This strong performance, coupled with advancements in its product development pipeline and positive clinical data, reinforces a positive outlook for the company's operational and financial trajectory.